Drugs / TAK-058
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02614586 | Dec 2015 → Apr 2016 | schizophrenia | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02389881 | Feb → Dec 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02153099 | Jun → Nov 2014 | — | Takeda | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03669250 Comparator | Nov 2018 → Mar 2020 | schizophrenia | Cerevance Alpha, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02153099 ↗ |
| Known as | CVN058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669250 ↗ |
| Known as | ENV8058 | “The drug being tested in this study is called ENV8058 (also known as TAK-058).” NCT02153099 ↗ |
| Route | Oral | “when administered as a single oral dose in healthy adults” NCT02153099 ↗ |